Published in Cell Growth Differ on July 01, 1999
The Drosophila cyclin D-Cdk4 complex promotes cellular growth. EMBO J (2000) 2.19
Loss of presenilin 1 is associated with enhanced beta-catenin signaling and skin tumorigenesis. Proc Natl Acad Sci U S A (2001) 2.00
Enhanced malignant tumorigenesis in Cdk4 transgenic mice. Oncogene (2004) 1.15
Differential expression of cyclin D1 in the human hair follicle. Am J Pathol (2003) 1.10
Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis. Cancer Res (2009) 1.07
Transgenic expression of cyclin-dependent kinase 4 results in epidermal hyperplasia, hypertrophy, and severe dermal fibrosis. Am J Pathol (2001) 1.05
Cyclin D2 overexpression in transgenic mice induces thymic and epidermal hyperplasia whereas cyclin D3 expression results only in epidermal hyperplasia. Am J Pathol (2000) 1.04
Selective anticancer activity of a hexapeptide with sequence homology to a non-kinase domain of Cyclin Dependent Kinase 4. Mol Cancer (2011) 0.80
Cyclin D1 expression in Bowen's disease and cutaneous squamous cell carcinoma. Mol Clin Oncol (2014) 0.80
Enhanced skin carcinogenesis and lack of thymus hyperplasia in transgenic mice expressing human cyclin D1b (CCND1b). Mol Carcinog (2009) 0.79
Unexpected reduction of skin tumorigenesis on expression of cyclin-dependent kinase 6 in mouse epidermis. Am J Pathol (2010) 0.78
Developmental stage determines estrogen receptor alpha expression and non-genomic mechanisms that control IGF-1 signaling and mammary proliferation in mice. J Clin Invest (2011) 0.78
Combined effect of cyclin D3 expression and abrogation of cyclin D1 prevent mouse skin tumor development. Cell Cycle (2012) 0.77
Cyclin D3 deficiency inhibits skin tumor development, but does not affect normal keratinocyte proliferation. Oncol Lett (2017) 0.75
Induction of cyclin D1 overexpression by activated ras. Oncogene (1994) 2.35
Interdependence of cortical thymic epithelial cell differentiation and T-lineage commitment. Proc Natl Acad Sci U S A (1998) 2.10
Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog (1999) 1.95
Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev (1998) 1.88
VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene (1998) 1.61
Detection of loss of heterozygosity in formalin-fixed paraffin-embedded tumor specimens by the polymerase chain reaction. Am J Pathol (1991) 1.59
High susceptibility to ultraviolet-induced carcinogenesis in mice lacking XPC. Nature (1995) 1.57
p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst (1993) 1.54
Expression of cyclin D1 in epithelial tissues of transgenic mice results in epidermal hyperproliferation and severe thymic hyperplasia. Proc Natl Acad Sci U S A (1996) 1.51
p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol (1999) 1.46
Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53. Proc Natl Acad Sci U S A (1998) 1.38
Frequent loss of heterozygosity in human primary squamous cell and colon carcinomas at 7q31.1: evidence for a broad range tumor suppressor gene. Cancer Res (1995) 1.36
E2F1 has both oncogenic and tumor-suppressive properties in a transgenic model. Mol Cell Biol (1999) 1.29
Mutational and functional analyses reveal that ST7 is a highly conserved tumor-suppressor gene on human chromosome 7q31. Nat Genet (2001) 1.28
Deregulated expression of E2F1 induces hyperplasia and cooperates with ras in skin tumor development. Oncogene (1998) 1.25
(C-A)n microsatellite repeat D7S522 is the most commonly deleted region in human primary breast cancer. Proc Natl Acad Sci U S A (1994) 1.24
Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7q31.1. Cancer Res (1994) 1.23
Overexpression of cyclin D1 in mouse skin carcinogenesis. Oncogene (1993) 1.22
Nonrandom duplication of the chromosome bearing a mutated Ha-ras-1 allele in mouse skin tumors. Proc Natl Acad Sci U S A (1990) 1.20
Progressive dysplasia and aneuploidy are hallmarks of mouse skin papillomas: relevance to malignancy. Proc Natl Acad Sci U S A (1987) 1.19
Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. Cell Growth Differ (1996) 1.15
Early overexpression of cyclin D1 protein in mouse skin carcinogenesis. Carcinogenesis (1995) 1.14
Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res (1996) 1.13
ras activity and cyclin D1 expression: an essential mechanism of mouse skin tumor development. Mol Carcinog (1999) 1.12
A variant of pulmonary alveolar microlithiasis in nackt mice. Vet Pathol (2002) 1.11
Sequential trisomization of chromosomes 6 and 7 in mouse skin premalignant lesions. Mol Carcinog (1989) 1.06
Aneuploidy, an early event in mouse skin tumor development. Carcinogenesis (1986) 1.06
Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1. Oncogene (1998) 1.06
Allelic loss at 7q31.1 in human primary ovarian carcinomas suggests the existence of a tumor suppressor gene. Oncogene (1995) 1.05
Transgenic expression of cyclin-dependent kinase 4 results in epidermal hyperplasia, hypertrophy, and severe dermal fibrosis. Am J Pathol (2001) 1.05
Increased expression of mutated Ha-ras during premalignant progression in SENCAR mouse skin. Mol Carcinog (1999) 1.05
Deregulated expression of cell-cycle proteins during premalignant progression in SENCAR mouse skin. Oncogene (1998) 1.05
Angiogenesis is an early event in the development of chemically induced skin tumors. Carcinogenesis (1998) 1.04
Cyclin D2 overexpression in transgenic mice induces thymic and epidermal hyperplasia whereas cyclin D3 expression results only in epidermal hyperplasia. Am J Pathol (2000) 1.04
A direct cytogenetic technique for mouse skin carcinomas and papillomas. Cancer Genet Cytogenet (1986) 1.03
Multistage chemical carcinogenesis protocols produce spindle cell carcinomas of the mouse skin. Carcinogenesis (1989) 1.02
Alterations of the p53 tumor suppressor gene during mouse skin tumor progression. Cancer Res (1991) 1.02
Terminal differentiation-resistant epidermal cells in mice undergoing two-stage carcinogenesis. Cancer Res (1987) 1.01
Alterations of p53, cyclin D1, Rb, and H-ras in human oral carcinomas related to tobacco use. Cancer (1998) 0.98
Myc lacks E2F1's ability to suppress skin carcinogenesis. Oncogene (2001) 0.98
Coordinated changes in cell cycle machinery occur during keratinocyte terminal differentiation. Oncogene (1999) 0.97
p53, Rb, and cyclin D1 expression in human oral verrucous carcinomas. Cancer (1996) 0.97
Synchronized proliferation induced by 12-O-tetradecanoylphorbol-13-acetate treatment of mouse skin: an in vivo model for cell cycle regulation. Cell Growth Differ (1998) 0.97
Rapid detection of xenotransplanted human tissues using in situ hybridization. Am J Pathol (1986) 0.96
Aberrant expression of the simple epithelial type II keratin 8 by mouse skin carcinomas but not papillomas. Mol Carcinog (1992) 0.96
The effect of vitamin E acetate on ultraviolet-induced mouse skin carcinogenesis. Mol Carcinog (1998) 0.96
Transgenic expression of cyclin D1 in thymic epithelial precursors promotes epithelial and T cell development. J Immunol (2000) 0.96
Inhibition of tumorigenicity of a murine squamous cell carcinoma (SCC) cell line by a putative tumor suppressor gene on human chromosome 7. Oncogene (1994) 0.96
Definitive functional evidence for a tumor suppressor gene on human chromosome 7q31.1 neighboring the Fra7G site. Oncogene (2000) 0.95
During development, 17alpha-estradiol is a potent estrogen and carcinogen. Environ Health Perspect (1997) 0.92
Regulation of the differentiation-related gene Drg-1 during mouse skin carcinogenesis. Mol Carcinog (2001) 0.92
Sequential development of aneuploidy, keratin modifications, and gamma-glutamyltransferase expression in mouse skin papillomas. Cancer Res (1988) 0.91
Cytogenetic, molecular and functional evidence for novel tumor suppressor genes on the long arm of human chromosome 7. Mol Carcinog (1996) 0.90
Differential effects of estradiol-17 beta and progesterone on the proliferation of glandular and luminal cells of rabbit uterine epithelium. Biol Reprod (1981) 0.90
Overlapping loss of heterozygosity by mitotic recombination on mouse chromosome 7F1-ter in skin carcinogenesis. Proc Natl Acad Sci U S A (1991) 0.89
Transgenic expression of E2F3a causes DNA damage leading to ATM-dependent apoptosis. Oncogene (2008) 0.88
Alterations in the expression of uvomorulin and Na+,K(+)-adenosine triphosphatase during mouse skin tumor progression. Am J Pathol (1992) 0.87
Characterization of skin tumor promotion and progression by chrysarobin in SENCAR mice. Cancer Res (1987) 0.87
Estrogen and progesterone regulation of proliferation, migration, and loss in different target cells of rabbit uterine epithelium. Endocrinology (1984) 0.87
Temporal relationship between rabbit uterine epithelium proliferation and uteroglobin production. Biol Reprod (1981) 0.87
Estrogen and progesterone regulation of proliferation and differentiation of rabbit uterine epithelium. Prog Clin Biol Res (1984) 0.87
Induction of mammary cancer and lymphoma by multiple, low oral doses of 7,12-dimethylbenz[a]anthracene in SENCAR mice. Carcinogenesis (1997) 0.86
Beta2 integrin/ICAM-1 adhesion molecule interactions in cutaneous inflammation and tumor promotion. Carcinogenesis (1998) 0.86
Squamous cell hyperplastic foci: precursors of cutaneous papillomas induced in SENCAR mice by a two-stage carcinogenesis regimen. Cancer Res (1998) 0.84
Evidence that initiated keratinocytes clonally expand into multiple existing hair follicles during papilloma histogenesis in SENCAR mouse skin. Mol Carcinog (1997) 0.84
Inhibition by 2,6-dithiopurine and thiopurinol of binding of a benzo(a)pyrene diol epoxide to DNA in mouse epidermis and of the initiation phase of two-stage tumorigenesis. Cancer Res (1991) 0.84
Immunohistochemical detection of filaggrin in preneoplastic and neoplastic lesions of the human oral mucosa. Am J Pathol (1985) 0.84
Mouse chromosome 7. Mamm Genome (1992) 0.83
Changes in protein expression during multistage mouse skin carcinogenesis. Mol Carcinog (1997) 0.83
Regulation of ciliogenesis and proliferation of uterine epithelium by 20 alpha-hydroxy-pregn-4-en-3-one administration and withdrawal in ovariectomized rabbits. Biol Reprod (1981) 0.83
Changes in keratin expression during 7,12-dimethylbenz[a]anthracene-induced hamster cheek pouch carcinogenesis. Cancer Res (1990) 0.83
Persistence of p53 mutations and resistance of keratinocytes to apoptosis are associated with the increased susceptibility of mice lacking the XPC gene to UV carcinogenesis. Oncogene (1999) 0.83
Early expression of type I K13 keratin in the progression of mouse skin papillomas. Carcinogenesis (1990) 0.83
Ultrastructure of a vaginal myxoma of a rat. Vet Pathol (1974) 0.83
Mouse chromosome 7. Mamm Genome (1994) 0.83
Characterization of an inbred strain of the SENCAR mouse that is highly sensitive to phorbol esters. Carcinogenesis (1987) 0.81
Papillomas at high risk for malignant progression arising both early and late during two-stage carcinogenesis in SENCAR mice. Carcinogenesis (1998) 0.81
Expression of keratins in mouse vaginal epithelium. Differentiation (1994) 0.81
The CD4 T cell-deficient mouse mutation nackt (nkt) involves a deletion in the cathepsin L (CtsI) gene. Immunogenetics (2001) 0.81
Positive immunohistochemical staining of p53 and cyclin D in advanced mouse skin tumors, but not in precancerous lesions produced by benzo[a]pyrene. Carcinogenesis (1995) 0.81
Critical genetic determinants and molecular events in multistage skin carcinogenesis. Symp Fundam Cancer Res (1986) 0.80
Cutaneous changes during prolonged application of 12-O-tetradecanoylphorbol-13-acetate on mouse skin and residual effects after cessation of treatment. Cancer Res (1985) 0.80
Cyclin D2 and cyclin D3 play opposite roles in mouse skin carcinogenesis. Oncogene (2006) 0.80
Altered expression of transforming growth factor-beta 1 mRNA and protein in mouse skin carcinogenesis. Mol Carcinog (1994) 0.80
Deregulated expression of cyclin D1 overrides antimitogenic signals. Oncogene (2000) 0.80
Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology (1995) 0.80
Effects of chronic topical application of 12-O-tetradecanoylphorbol-13-acetate on the skin and internal organs of SENCAR mice. Environ Health Perspect (1986) 0.80
Cytogenetic evidence for gene amplification in mouse skin carcinogenesis. Cancer Res (1986) 0.80
Immunohistochemical demonstration of keratins in oral mucosa lesions. Acta Odontol Latinoam (1984) 0.79
N-methyl-N-nitrosourea alters thymocyte subset distribution and targets immature CD4-8+ cells for lymphoma development. Cancer Res (1991) 0.79
Low frequency of codon 61 Ha-ras mutations and lack of keratin 13 expression in 7,12-dimethylbenz[a]-anthracene-induced hamster skin tumors. Mol Carcinog (1993) 0.79
Cytogenetic profile of mouse skin tumors induced by the viral Harvey-ras gene. Carcinogenesis (1988) 0.79